PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo

  • Authors:
    • Xinting Pan
    • Qingyun Zhu
    • Yunbo Sun
    • Liandi Li
    • Yunpeng Zhu
    • Zhihui Zhao
    • Jianxin Zuo
    • Wei Fang
    • Kun Li
  • View Affiliations

  • Published online on: February 11, 2015     https://doi.org/10.3892/ijmm.2015.2096
  • Pages: 995-1002
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Endothelial PAS domain protein 1 (EPAS1) is a hypoxia-inducible protein that contributes to tumor progression. Hypoxia is involved in tumor aggressiveness and resistance to chemotherapy and ionizing radiation. In this study, we aimed to assess the effects of EPAS1 silencing using polyethylenimine-poly(lactide-coglycolide) (PLGA)/poloxamer nanoparticles loaded with EPAS1 siRNA on BxPC-3 pancreatic cancer cells and in a mouse model of ectopic pancreatic cancer. PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA or scramble siRNA were prepared using the emulsion/solvent evaporation method. BxPC-3 pancreatic cancer cells were cultured under hypoxic conditions and treated with or without the nanoparticles. MTT and apoptosis assays were then performed. A xenograft nude mouse model of pancreatic cancer was established and the mice were treated with or without the nanoparticles. The mRNA and protein expression levels of EPAS1 in the tumor tissues were determined by semi-quantitative RT-PCR and western blot analysis, respectively. Vascular endothelial growth factor (VEGF) and tumor microvessel density indicated by CD34 were determined by immunohistochemistry. The in vitro release of EPAS1 siRNA from the nanoparticles exerted a sustained-release effect. EPAS1 siRNA nanoparticles inhibited BxPC-3 cell proliferation, and induced cell apoptosis under hypoxic conditions, compared with the nanoparticles loaded with scramble siRNA (all P<0.05). EPAS1 expression was significantly decreased in the pancreatic tumors of the mice injected with the nanoparticles loaded with EPAS1 siRNA. The pancreatic tumors of the mice injected with nanoparticles loaded with EPAS1 siRNA were significantly smaller in size and had a lower number of microvessels and a percentage of VEGF-positive cells compared with those of the mice injected with the nanoparticles loaded with scramble siRNA (all P<0.05). In conclusion, the results from the present study suggest that PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA inhibit pancreatic cancer cell proliferation, induce cell apoptosis under hypoxic conditions and significantly inhibit the formation of microvessels and tumor growth in vivo.
View Figures
View References

Related Articles

Journal Cover

April-2015
Volume 35 Issue 4

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Pan X, Zhu Q, Sun Y, Li L, Zhu Y, Zhao Z, Zuo J, Fang W and Li K: PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo. Int J Mol Med 35: 995-1002, 2015
APA
Pan, X., Zhu, Q., Sun, Y., Li, L., Zhu, Y., Zhao, Z. ... Li, K. (2015). PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo. International Journal of Molecular Medicine, 35, 995-1002. https://doi.org/10.3892/ijmm.2015.2096
MLA
Pan, X., Zhu, Q., Sun, Y., Li, L., Zhu, Y., Zhao, Z., Zuo, J., Fang, W., Li, K."PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo". International Journal of Molecular Medicine 35.4 (2015): 995-1002.
Chicago
Pan, X., Zhu, Q., Sun, Y., Li, L., Zhu, Y., Zhao, Z., Zuo, J., Fang, W., Li, K."PLGA/poloxamer nanoparticles loaded with EPAS1 siRNA for the treatment of pancreatic cancer in vitro and in vivo". International Journal of Molecular Medicine 35, no. 4 (2015): 995-1002. https://doi.org/10.3892/ijmm.2015.2096